BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37287914)

  • 1. Risks of prostate cancer and mortality in the city of Sharjah, United Arab Emirates.
    Al Shareef Z; Al-Shahrabi R; Saheb Sharif-Askari F; Alshamsi Y; Zarooni AA; AlKhayyal N; Soliman SSM; Bendardaf R; Halwani R
    Front Oncol; 2023; 13():1180902. PubMed ID: 37287914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Al Shareef Z; Al-Shahrabi R; Saheb Sharif-Askari F; AlDhmanie A; Alshamsi Y; Zarooni AA; Mahmoud RA; Soliman SSM; Halwani R; Bendardaf R
    Prostate; 2024 Feb; 84(2):185-192. PubMed ID: 37969038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL?
    Erdogan A; Polat S; Keskin E; Turan A
    Aging Male; 2020 Mar; 23(1):59-65. PubMed ID: 30862227
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study.
    Park DH; Yu JH
    Transl Cancer Res; 2023 Mar; 12(3):502-514. PubMed ID: 37033352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
    Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
    J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer.
    Chaoying L; Chao M; Xiangrui Y; Yingjian H; Gang Z; Yunhan R; Yu G
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):391-398. PubMed ID: 35113414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
    Chung JH; Yu J; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
    J Korean Med Sci; 2020 Oct; 35(41):e342. PubMed ID: 33107227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
    Wang C; Wang YY; Wang SY; Ding JX; Ding M; Ruan Y; Wang XH; Jing YF; Han BM; Xia SJ; Jiang CY; Zhao FJ
    Asian J Androl; 2021; 23(4):415-420. PubMed ID: 33473011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.
    Sheikh M; Al-Saeed O; Kehinde EO; Sinan T; Anim JT; Ali Y
    Int Urol Nephrol; 2005; 37(4):721-6. PubMed ID: 16362587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of prostate volume on clinical parameters in prostate cancer screening.
    Shan J; Geng X; Lu Y; Liu Z; Zhu H; Zhou R; Zhang Z; Gang X; Zhang D; Shi H
    J Clin Lab Anal; 2022 Oct; 36(10):e24700. PubMed ID: 36098911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Analysis of Biparametric MRI and Prostate-Specific Antigen Density: Role in the Prebiopsy Diagnosis of Gleason Score 7 or Greater Prostate Cancer.
    Lee SJ; Oh YT; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2018 Sep; 211(3):W166-W172. PubMed ID: 30016148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.